Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investment in QuantaSol

28 Jun 2007 07:02

Imperial Innovations Group plc28 June 2007 28 June 2007 Imperial Innovations Group plc ("Imperial Innovations") Investment in QuantaSol Limited Imperial Innovations Group plc, the technology commercialisation and investmentcompany (AIM: IVO) today announces that a £1.35 million investment round intoQuantasol has closed. As part of this round Imperial Innovations has invested£300,000 on a milestone basis in QuantaSol Limited (QuantaSol), a developer ofphotovoltaics (PV) - solar power technology that converts sunlight directly toelectricity. The round also included significant funding from Low CarbonAccelerator, NetScientific Ltd and Numis Corporation PLC. Following theinvestment, Imperial Innovations owns a 24% stake in the company. QuantaSol plans to provide solar photovoltaic cells for use in Concentrating PV(CPV) systems for the fast growing utility-scale solar power generation market.The company will use the funds to produce prototypes of its Quantum WellPhotovoltaic (QWPV) cells and to engage with potential customers for these solarPV cells. CPV systems use relatively inexpensive optics such as mirrors or lenses toconcentrate or focus light from a broad collection area onto a much smaller areaof active semiconductor PV cell material. Since the PV semiconductor materialusually dominates the costs of a solar PV system, reducing the amount of PVmaterial required to capture a given amount of sunlight leads to substantiallylower system cost and cost per watt of output. QuantaSol's "third generation"cells are based on Gallium arsenide (GaAs) and other III-V semiconductormaterials. These materials are more expensive than silicon, which is commonlyused for flat panel PV, but have more than double the photovoltaic efficiency.QuantaSol plans to manufacture single and multi-junction concentrator solarcells with efficiency levels of up to 40%. QuantaSol was formed in 2006 and is based on the research of Professor KeithBarnham, Emeritus Professor of Physics and Senior Research Investigator in theDepartment of Physics at Imperial College London; Dr. Massimo Mazzer, SeniorResearcher of the National Research Council of Italy; and Dr. John Roberts,Senior Research Scientist at The University of Sheffield. The company also has astrong and experienced management team in place which includes CEO Kevin Arthurwho has twenty-three years of international business development and operationalexperience in semiconductor manufacturing companies and technology start-ups. Following the investment, the board of QuantaSol will be strengthened furtherwith the appointment of Oliver Hemsley, CEO of Numis Corporation PLC, as anon-executive director. Susan Searle, Chief Executive, Imperial Innovations, said, "QuantaSol'stechnology is derived from strong research by a team of world-class scientists.We are keen to support them through the early stages and will continue to workwith them as they develop the company and become a significant player in thesolar energy market." Kevin Arthur, Chief Executive, QuantaSol, said, " We are very grateful for thesupport that we have received from Imperial Innovations, and are looking forwardto working with them and the rest of the investor group to take QuantaSolforward to become a major global supplier of third generation, high efficiencysolar cells." -Ends- For more information contact: Imperial InnovationsSusan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 M:CommunicationsPatrick d'Ancona / Harriet Totty +44 (0)20 7153 1590 JP Morgan Cazenove +44(0)20 7588 2828Steve Baldwin Notes to Editors About Imperial InnovationsImperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £26 million. The company's integrated approach encompassesthe identification of ideas, protection of intellectual property, developmentand licensing of technology and formation, incubation and investment intechnology businesses. A wide range of technologies are commercialised withinthe areas of healthcare, energy, environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in70 technology businesses and has completed 116 commercial agreements. ImperialInnovations also commercialises technologies originating from outside ImperialCollege through incubation contracts with the Carbon Trust and WRAP and hasrelationships with a number of multinational corporations including BAE Systems. Imperial Innovations has invested in a range of spin-out companies, includingThe Acrobot Company Limited, BioCeramic Therapeutics Limited, Cardiak Limited,Circassia Holdings Limited, deltaDOT Limited, Equinox Pharma Limited, FutureWaves PTE Limited, HeliSwirl Technologies Limited, InforSense Limited, IXICOLimited, Lontra Limited, Midaz Lasers Limited, NanoBioDesign Limited, NexeonLimited, NovaThera Limited, Thiakis Limited and Veryan Medical Limited. Imperial Innovations currently holds shares in four technology businesses nowlisted on AIM including the fuel cell company, Ceres Power plc. www.imperialinnovations.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Sep 20162:40 pmRNSHolding(s) in Company
24th Aug 20167:01 amRNSCell Medica and UCL collaboration
12th Jul 20167:02 amRNSCell Medica acquires Delenex Therapeutics
6th Jul 20167:00 amRNSEconic raises £5m to develop novel catalyst tech
30th Jun 201612:11 pmRNSPsiOxus and Bristol-Myers Squibb collaboration
28th Jun 20167:00 amRNSStorm Therapeutics raises £12m
21st Jun 20164:35 pmRNSPrice Monitoring Extension
21st Jun 20167:00 amRNSDirector's share purchase
20th Jun 20167:03 amRNSCircassia cat allergy Phase III study
17th Jun 20167:00 amRNSCell Medica and Baylor College of Medicine partner
16th Jun 201610:44 amRNSReplacement Holding(s) in Company
14th Jun 20163:20 pmRNSEdison issues outlook on Imperial Innovations)
14th Jun 20169:00 amRNSHolding(s) in Company
13th Jun 20167:00 amRNSAllotment of Deferred Placing Shares
31st May 20167:00 amRNSFeaturespace closes £6.2 million funding round
26th May 20167:00 amRNS£3 million funding round for Inflowmatix
11th May 201612:32 pmRNSDavid Newlands appointed Chairman
4th May 20164:35 pmRNSPrice Monitoring Extension
4th May 201611:08 amRNSNexeon raises £30m, plans development lab in Asia
4th May 20167:00 amRNSAnalyst and Investor day
29th Apr 20164:35 pmRNSPrice Monitoring Extension
29th Apr 201612:42 pmRNSSale of Innovations portfolio Stanmore Implants
7th Apr 20167:00 amRNSHalf Yearly Report
21st Mar 20167:00 amRNSDr Martin Knight to step down from the board
18th Mar 201612:40 pmRNSNotice of Results
17th Mar 20167:00 amRNSTopiVert reports successful Phase I clinical study
26th Feb 20168:39 amRNSHolding(s) in Company
25th Feb 20163:59 pmRNSHolding(s) in Company
25th Feb 20163:50 pmRNSHolding(s) in Company
25th Feb 20168:53 amRNSHolding(s) in Company
22nd Feb 20165:01 pmRNSAdmission of shares to trading on AIM
22nd Feb 201612:29 pmRNSResult of General Meeting
22nd Feb 20167:00 amRNS£13.5m funding round in Precision Ocular
11th Feb 20162:51 pmRNSHolding(s) in Company
8th Feb 20167:00 amRNSInnovations leads £5m Series A round in Aqdot
4th Feb 20166:08 pmRNSResult of Placing
4th Feb 20167:00 amRNSPlacing to raise £100 million
2nd Feb 20167:00 amRNSMISSION Therapeutics raises £60 million
26th Jan 20167:00 amRNSInivata completes £31.5m Series A funding round
25th Jan 20167:00 amRNSInnovations joins Apollo consortium
18th Jan 20167:00 amRNSInnovations invests £25m in new £50m UCL Tech Fund
2nd Dec 20157:00 amRNSKesios Therapeutics raises £19 million
19th Nov 20151:51 pmRNSResult of AGM
4th Nov 20151:40 pmRNSGrant of share options
28th Oct 20157:00 amRNSPosting of Annual Report and Notice of AGM
22nd Oct 20157:00 amRNSLeads £1.5m seed funding into AI pioneer, Telectic
14th Oct 20157:00 amRNSFinal Results
22nd Sep 20154:10 pmRNSNotice of Results
12th Aug 20157:00 amRNSIssue of Equity
4th Aug 20157:01 amRNS£2.5m funding round in Oxford Biotrans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.